3 terminated, 2 active not recruiting, 2 completed, 2 unknown. 7 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 2, Unknown 2, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 4 | Terminated 2, Active not recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow SEphB4-HSA: new trials by email Literature Review of SEphB4-HSA trials Research Report on SEphB4-HSA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors SEphB4-HSA, Pembrolizumab, Gemcitabine - Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma | Phase 2 / Phase 3 | Recruiting | Vasgene Therapeutics, Inc | 700 | 2025-03-15 | 2025-04-03 |
| sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer Pharmacokinetic Study, Recombinant EphB4-HSA Fusion Protein - Recurrent Bladder Carcinoma, Bladder Cancer Stage 0 | Phase 1 | Withdrawn | University of Southern California | 2023-08-01 | 2023-06-26 | |
| A Study of sEphB4-HSA in Kaposi Sarcoma sEphB4-HSA - Kaposi Sarcoma | Phase 2 | Unknown | Vasgene Therapeutics, Inc | 65 | 2020-09-17 | 2024-05-02 |
| sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Recombinant EphB4-HSA Fusion Protein - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Unknown | Northwestern University | 14 | 2019-09-20 | 2022-04-27 |
| EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia Cytarabine, Laboratory Biomarker Analysis, Recombinant EphB4-HSA Fusion Protein - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Phase 1 | Terminated | University of Southern California | 3 | 2018-05-09 | 2021-11-30 |
| sEphB4-HSA in Treating Patients With Kaposi Sarcoma Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment - Skin Kaposi Sarcoma | Phase 2 | Completed | AIDS Malignancy Consortium | 23 | 2018-02-13 | 2026-06-01 |
| Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent Azacitidine, Decitabine, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Terminated | University of Southern California | 7 | 2017-04-20 | 2026-06-08 |
| Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Laboratory Biomarker Analysis, Pembrolizumab, Recombinant EphB4-HSA Fusion Protein - ALK Gene Mutation, BRAF Gene Mutation | Phase 2 | Completed | University of Southern California | 42 | 2017-03-10 | 2025-10-22 |
| Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors Computed Tomography, Laboratory Biomarker Analysis, Pembrolizumab - Stage IV Bladder Urothelial Carcinoma, Prostate Cancer | Phase 2 | Active not recruiting | University of Southern California | 70 | 2016-11-21 | 2026-06-09 |
| sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Radical Cystectomy - Infiltrating Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma | Phase 1 | Terminated | University of Southern California | 2 | 2016-08-02 | 2021-11-24 |
| Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors Cisplatin, Docetaxel, Gemcitabine Hydrochloride - Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Active not recruiting | University of Southern California | 61 | 2015-09-03 | 2026-04-29 |
Prostatic Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Transitional Cell (2) · Leukemia, Myeloid, Acute (2) · Squamous Cell Carcinoma of Head and Neck (2) · Urinary Bladder Neoplasms (2) · Carcinoma, Renal Cell (1) · Disease Progression (1) · Gallbladder Neoplasms (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Pancreatic Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
University of Southern California (7) · Vasgene Therapeutics, Inc (2) · AIDS Malignancy Consortium (1) · Northwestern University (1)
United States (11)
Sarmad Sadeghi, MD (2) · Akil Merchant, MD (1) · Anthony El-Khoueiry (1) · Carl Millner, M.D. (1) · Casey O'Connell, MD (1) · David I Quinn, MD (1) · Ida Wong-Sefidan (1) · Jorge Nieva, MD (1) · Maha H Hussain, M.D. (1) · Monish Aron, MD (1)
P30CA014089 (7), P30CA060553 (1), U01CA121947 (1)